Turnstone Biologics Inc.; Ottawa, Ontario, Canada

Turnstone raised $41.4m through its Series B round from new investors OrbiMed and F-Prime, which both take board seats, along with returning backers FACIT and Versant Ventures. The company closed its Series A round in November 2015. (Also see "FINANCE ROUNDUP: A New VC Fund, A $60m Collaboration Boost, And 14 Funding Rounds" - Scrip, 19 November, 2015.)

Funds will support completion in 2017 of an ongoing Phase I/II trial with Turnstone's lead oncolytic Maraba virus candidate for melanoma. The company plans to expand indications for that therapy – in combination with a checkpoint inhibitor – to include non-small cell lung cancer, and will continue work on two preclinical Maraba virus-based therapies for other cancers.

VC Roundup: Magenta Raises $48.5m To Improve Stem Cell Transplants

More from Business

More from Scrip